In vivo grade recombinant natural and engineered rabbit IgG Fc proteins (rIgG Fc), and recombinant rabbit IgG isotype control antibody and mutants are available. Biotinylated rIgG Fc, and rIgG Fc with Avi-, His-, and Flag-tags are also available.
Cheapest in vivo grade recombinant human IgG1 kappa isotype control and mutants. Low or no specific binding to human samples tested. Humanized variable regions, and human IgG1 kappa constant regions. Chimeric versions and premium grade (endotoxin ≤0.05 EU/mg)...
Recombinant mouse IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Recombinant rat IgG2a isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Recombinant rat IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Recombinant Mouse IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Recombinant mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
GMP Mesenchymal Stem Cell Serum-Free Medium 2.0 is a premium, xeno-free and serum-free medium specifically designed for the clinical-scale expansion and characterization of human mesenchymal stem cells (MSCs). It uses a completely serum-free, animal-derived component-free,...
Recombinant Human Fab Fragment isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Recombinant Mouse Fab Fragment isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
